Self-Assembly Catalase Nanocomplex Conveyed by Bacterial Vesicles for Oxygenated Photodynamic Therapy and Tumor Immunotherapy

References

• Zou L, Wang H, He B, et al. Current approaches of photothermal therapy in treating cancer metastasis with nanotherapeutics. Theranostics. 2016;6(6):762–772. doi:10.7150/thno.14988
   PubMed Web of Science ®Google Scholar
• Dolmans DEJGJ, Fukumura D, Jain RK. Photodynamic therapy for cancer. Nat Rev Cancer. 2003;3(5):380–387. doi:10.1038/nrc1071
   PubMed Web of Science ®Google Scholar
• Düzgüneş N, Piskorz J, Skupin-Mrugalska P, Goslinski T, Mielcarek J, Konopka K. Photodynamic therapy of cancer with liposomal photosensitizers. Ther Deliv. 2018;9(11):823–832. doi:10.4155/tde-2018-0050
   PubMed Web of Science ®Google Scholar
• Kwiatkowski S, Knap B, Przystupski D, et al. Photodynamic therapy – mechanisms, photosensitizers and combinations. Biomed Pharmacother. 2018;106:1098–1107. doi:10.1016/j.biopha.2018.07.049
   PubMed Web of Science ®Google Scholar
• Li M, Shao Y, Kim JH, et al. Unimolecular photodynamic O2-economizer to overcome hypoxia resistance in phototherapeutics. ACS Appl Mater Interfaces. 2020;142(11). doi:10.1021/jacs.0c00734
   Web of Science ®Google Scholar
• You Q, Zhang K, Liu J, et al. Persistent regulation of tumor hypoxia microenvironment via a bioinspired Pt-based oxygen nanogenerator for multimodal imaging-guided synergistic phototherapy. Adv Sci. 2020;7(17). doi:10.1002/advs.201903341
   Web of Science ®Google Scholar
• Damrongrungruang T, Kitchindaopat N, Thanasothon P, et al. Effects of photodynamic therapy with azulene on peripheral blood mononuclear cell viability and singlet oxygen formation. Photodiagnosis Photodyn Ther. 2018;24:318–323. doi:10.1016/j.pdpdt.2018.10.015
   PubMed Web of Science ®Google Scholar
• Chen H, Tian J, He W, Guo Z. H 2 O 2 -activatable and O 2 -evolving nanoparticles for highly efficient and selective photodynamic therapy against hypoxic tumor cells. J Am Chem Soc. 2015;137(4):1539–1547. doi:10.1021/ja511420n
   PubMed Web of Science ®Google Scholar
• Xu J, Xu L, Wang C, et al. Near-infrared-triggered photodynamic therapy with multitasking upconversion nanoparticles in combination with checkpoint blockade for immunotherapy of colorectal cancer. ACS Nano. 2017;11(5):4463–4474. doi:10.1021/acsnano.7b00715
   PubMed Web of Science ®Google Scholar
• Wan Y, Fu L, Li C, Lin J, Huang P. Conquering the hypoxia limitation for photodynamic therapy. Adv Mater. 2021;33(48):2103978. doi:10.1002/adma.202103978
   PubMed Web of Science ®Google Scholar
• Gunaydin G, Gedik ME, Ayan S. Photodynamic therapy—current limitations and novel approaches. Front Chem. 2021;9:691697. doi:10.3389/fchem.2021.691697
   PubMed Web of Science ®Google Scholar
• Ayan S, Gunaydin G, Yesilgul-Mehmetcik N, Gedik ME, Seven O, Akkaya EU. Proof-of-principle for two-stage photodynamic therapy: hypoxia triggered release of singlet oxygen. Chem Commun. 2020;56(94):14793–14796. doi:10.1039/D0CC06031C
   PubMed Web of Science ®Google Scholar
• Wang D, Wu H, Phua SZF, et al. Self-assembled single-atom nanozyme for enhanced photodynamic therapy treatment of tumor. Nat Commun. 2020;11(1):357. doi:10.1038/s41467-019-14199-7
   PubMed Web of Science ®Google Scholar
• Shen Z, Ma Q, Zhou X, et al. Strategies to improve photodynamic therapy efficacy by relieving the tumor hypoxia environment. NPG Asia Mater. 2021;13(1):39. doi:10.1038/s41427-021-00303-1
   Web of Science ®Google Scholar
• Phua SZF, Yang G, Lim WQ, et al. Catalase-integrated hyaluronic acid as nanocarriers for enhanced photodynamic therapy in solid tumor. ACS Nano. 2019;13(4):4742–4751. doi:10.1021/acsnano.9b01087
   PubMed Web of Science ®Google Scholar
• Cheng X, He L, Xu J, et al. Oxygen-producing catalase-based prodrug nanoparticles overcoming resistance in hypoxia-mediated chemo-photodynamic therapy. Acta Biomater. 2020;112:234–249. doi:10.1016/j.actbio.2020.05.035
   PubMed Web of Science ®Google Scholar
• Tu H, Sun H, Lin Y, et al. Oxidative stress upregulates PDCD4 expression in patients with gastric cancer via miR-21. Curr Pharm Des. 2014;20(11):1917–1923. doi:10.2174/13816128113199990547
   PubMed Web of Science ®Google Scholar
• Tefik T, Kucukgergin C, Sanli O, Oktar T, Seckin S, Ozsoy C. Manganese superoxide dismutase Ile58Thr, catalase C-262T and myeloperoxidase G-463A gene polymorphisms in patients with prostate cancer: relation to advanced and metastatic disease. BJU Int. 2013;112(4):E406–E414. doi:10.1111/bju.12176
   PubMed Web of Science ®Google Scholar
• Huang Y, Fang W, Wang Y, Yang W, Xiong B. Transforming growth factor-β1 induces glutathione peroxidase-1 and protects from H 2O 2-induced cell death in colon cancer cells via the Smad2/ERK1/2/HIF-1α pathway. Int J Mol Med. 2012;29(5):906–912. doi:10.3892/ijmm.2012.901
   PubMed Web of Science ®Google Scholar
• Arnaut LG, Pereira MM, Dąbrowski JM, et al. Photodynamic therapy efficacy enhanced by dynamics: the role of charge transfer and photostability in the selection of photosensitizers. Chem Eur J. 2014;20(18):5346–5357. doi:10.1002/chem.201304202
   PubMed Web of Science ®Google Scholar
• Gündüz EÖ, Gedik ME, Günaydın G, Okutan E. Amphiphilic fullerene BODIPY photosensitizers for targeted photodynamic therapy. Chem Med Chem. 2021;17. doi:10.1002/cmdc.202100693
   Web of Science ®Google Scholar
• Jiang W, Tan Y, Yin JF, et al. Self-Assembly of amphiphilic BODIPY derivative and its nanoparticles as a photosensitizer for photodynamic therapy in corneal neovascularization. Colloids Surf a Physicochem Eng Asp. 2019;579:123706. doi:10.1016/j.colsurfa.2019.123706
   Web of Science ®Google Scholar
• Fan Z, Dai X, Lu Y, et al. Enhancing targeted tumor treatment by near IR light-activatable photodynamic-photothermal synergistic therapy. Mol Pharm. 2014;11(4):1109–1116. doi:10.1021/mp4002816
   PubMed Web of Science ®Google Scholar
• Cheng L, Gong H, Zhu W, et al. PEGylated Prussian blue nanocubes as a theranostic agent for simultaneous cancer imaging and photothermal therapy. Biomaterials. 2014;35(37):9844–9852. doi:10.1016/j.biomaterials.2014.09.004
   PubMed Web of Science ®Google Scholar
• Peng JR, Qi TT, Liao JF, et al. Mesoporous magnetic gold ‘nanoclusters’ as theranostic carrier for chemo-photothermal co-therapy of breast cancer. Theranostics. 2014;4(7):678–692. doi:10.7150/thno.7869
   PubMed Web of Science ®Google Scholar
• Fu X, Yang Z, Deng T, et al. A natural polysaccharide mediated MOF-based Ce6 delivery system with improved biological properties for photodynamic therapy. J Mater Chem B. 2020;8(7):1481–1488. doi:10.1039/c9tb02482d
   PubMed Web of Science ®Google Scholar
• Liu J, Han J, Kang Z, et al. In vivo near-infrared photothermal therapy and computed tomography imaging of cancer cells using novel tungsten-based theranostic probe. Nanoscale. 2014;6(11):5770–5776. doi:10.1039/c3nr06292a
   PubMed Web of Science ®Google Scholar
• Chatterjee DK, Fong LS, Zhang Y. Nanoparticles in photodynamic therapy: an emerging paradigm. Adv Drug Deliv Rev. 2008;60(15):1627–1637. doi:10.1016/j.addr.2008.08.003
   PubMed Web of Science ®Google Scholar
• Xia AL, Xu Y, Lu XJ. Cancer immunotherapy: challenges and clinical applications. J Med Genet. 2019;56(1):1–3. doi:10.1136/jmedgenet-2018-105852
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Chan TA, Kroemer G, Wolchok JD, López-Soto A. The hallmarks of successful anticancer immunotherapy. Sci Transl Med. 2018;10:459. doi:10.1126/scitranslmed.aat7807
   Web of Science ®Google Scholar
• Yang Y. Cancer immunotherapy: harnessing the immune system to battle cancer. J Clin Invest. 2015;125(9):3335–3337. doi:10.1172/JCI83871
   PubMed Web of Science ®Google Scholar
• Zhai Y, He X, Li Y, et al. A splenic-targeted versatile antigen courier: iPSC wrapped in coalescent erythrocyte-liposome as tumor nanovaccine. Sci Adv. 2021;7(35):eabi6326. doi:10.1126/sciadv.abi6326
   PubMed Web of Science ®Google Scholar
• Riley RS, June CH, Langer R, Mitchell MJ. Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov. 2019;18(3):175–196. doi:10.1038/s41573-018-0006-z
   PubMed Web of Science ®Google Scholar
• Gujrati V, Kim S, Kim SH, et al. Bioengineered bacterial outer membrane vesicles as cell-specific drug-delivery vehicles for cancer therapy. ACS Nano. 2014;8(2):1525–1537. doi:10.1021/nn405724x
   PubMed Web of Science ®Google Scholar
• Kim OY, Park HT, Dinh NTH, et al. Bacterial outer membrane vesicles suppress tumor by interferon-γ-mediated antitumor response. Nat Commun. 2017;8(1):1–9. doi:10.1038/s41467-017-00729-8
   PubMed Web of Science ®Google Scholar
• Kaparakis-Liaskos M, Ferrero RL. Immune modulation by bacterial outer membrane vesicles. Nat Rev Immunol. 2015;15(6):375–387. doi:10.1038/nri3837
   PubMed Web of Science ®Google Scholar
• Qing S, Lyu C, Zhu L, et al. Biomineralized bacterial outer membrane vesicles potentiate safe and efficient tumor microenvironment reprogramming for anticancer therapy. Adv Mater. 2020;32(47):2002085. doi:10.1002/adma.202002085
   Web of Science ®Google Scholar
• Gao J, Wang S, Dong X, Wang Z. RGD-expressed bacterial membrane-derived nanovesicles enhance cancer therapy via multiple tumorous targeting. Theranostics. 2021;11(7):3301–3316. doi:10.7150/THNO.51988
   PubMed Web of Science ®Google Scholar
• Constantinidou A, Alifieris C, Trafalis DT. Targeting programmed cell death −1 (PD-1) and ligand (PD-L1): a new era in cancer active immunotherapy. Pharmacol Ther. 2019;194:84–106. doi:10.1016/j.pharmthera.2018.09.008
   PubMed Web of Science ®Google Scholar
• Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350–1355. doi:10.1126/science.aar4060
   PubMed Web of Science ®Google Scholar
• Qorraj M, Bruns H, Böttcher M, et al. The PD-1/PD-L1 axis contributes to immune metabolic dysfunctions of monocytes in chronic lymphocytic leukemia. Leukemia. 2017;31(2):470–478. doi:10.1038/leu.2016.214
   PubMed Web of Science ®Google Scholar
• Kim HS, Lee JH, Nam SJ, et al. Association of PD-L1 expression with tumor-infiltrating immune cells and mutation burden in high-grade neuroendocrine carcinoma of the lung. J Thorac Oncol. 2018;13(5):636–648. doi:10.1016/j.jtho.2018.01.008
   PubMed Web of Science ®Google Scholar
• Powles T, Eder JP, Fine GD, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014;515(7528):558–562. doi:10.1038/nature13904
   PubMed Web of Science ®Google Scholar
• Xu T, Ma Y, Yuan Q, et al. Enhanced ferroptosis by oxygen-boosted phototherapy based on a 2-in-1 nanoplatform of ferrous hemoglobin for tumor synergistic therapy. ACS Nano. 2020;14(3):3414–3425. doi:10.1021/acsnano.9b09426
   PubMed Web of Science ®Google Scholar
• Liu C, Cao Y, Cheng Y, et al. An open source and reduce expenditure ROS generation strategy for chemodynamic/photodynamic synergistic therapy. Nat Commun. 2020;11(1):1735. doi:10.1038/s41467-020-15591-4
   PubMed Web of Science ®Google Scholar
• Kim OY, Park HT, Dinh NTH, et al. Bacterial outer membrane vesicles suppress tumor by interferon-γ-mediated antitumor response. Nat Commun. 2017;8(1):626. doi:10.1038/s41467-017-00729-8
   PubMed Web of Science ®Google Scholar
• Chen Q, Bai H, Wu W, et al. Bioengineering bacterial vesicle-coated polymeric nanomedicine for enhanced cancer immunotherapy and metastasis prevention. Nano Lett. 2020;20(1):11–21. doi:10.1021/acs.nanolett.9b02182
   PubMed Web of Science ®Google Scholar